Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
ALK-HIP1 fusion
i
Other names:
NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor, HIP1, Huntingtin Interacting Protein 1, SHONgamma, SHONbeta, SHON
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
;
3092
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
ALK positive (74)
ALK negative (4)
EGFR negative + ALK negative (4)
EGFR expression + ALK positive (3)
ALK expression + PDGFRA expression (1)
ALK expression + PDGFRB expression (1)
ALK overexpression (1)
ALK positive + ROS1 positive (1)
ALK positive + YAP1 overexpression (1)
ALK positive + YES1 overexpression (1)
KRT7 positive + NKX2-1 positive + ALK overexpression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
ALK-HIP1 fusion
Non Small Cell Lung Cancer
ALK-HIP1 fusion
Non Small Cell Lung Cancer
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
alectinib
Sensitive: C3 – Early Trials
alectinib
Sensitive
:
C3
ALK-HIP1 fusion
Non Small Cell Lung Cancer
ALK-HIP1 fusion
Non Small Cell Lung Cancer
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
crizotinib
Sensitive: C3 – Early Trials
crizotinib
Sensitive
:
C3
ALK-HIP1 fusion
Non Small Cell Lung Cancer
ALK-HIP1 fusion
Non Small Cell Lung Cancer
ensartinib
Sensitive: C3 – Early Trials
ensartinib
Sensitive
:
C3
ensartinib
Sensitive: C3 – Early Trials
ensartinib
Sensitive
:
C3
ALK-HIP1 fusion
Lung Adenocarcinoma
ALK-HIP1 fusion
Lung Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
alectinib
Sensitive: C4 – Case Studies
alectinib
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.